Full-Time

Clinical Account Manager

Confirmed live in the last 24 hours

Travere Therapeutics

Travere Therapeutics

201-500 employees

Develops therapies for rare diseases

Compensation Overview

$158k - $205k/yr

Senior, Expert

Seattle, WA, USA

Remote

Candidates must live in their territory or immediate adjacency.

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Bachelor’s degree required in related discipline; life sciences or clinical background preferred. Equivalent combination of education and applicable job experience may be considered.
  • Minimum of 8 years of relevant pharmaceutical/biotech sales experience required.
  • 5+ years of relevant work experience calling on prescribers of specialized, high value products.
Responsibilities
  • This position will be responsible for all business-related activities within their geographic responsibility, including achieving sales goals, business planning, and expense control.
  • Primarily responsible for calling on Health Care Professionals (HCPs) specializing in Nephrology in targeted institutions and offices.
  • Engage with providers managing patients with rare kidney disease and provide education regarding the benefits of using Travere therapies.
  • Compliantly assist with steps to provide access of therapies for patients. This may include proper testing procedures, site of care determination and reimbursement process education.
  • Provide educational support to an underserved patient community.
Desired Qualifications
  • The ideal candidate will embody Travere’s core values: Courage, Community Spirit, Patient Focus and Teamwork
  • Candidates must demonstrate a consistent track record of sales success including quantifiable/documented sales accomplishments and awards
  • Experience in rare disease or highly specialized products preferred
  • Prior experience calling on academic institutions preferred
  • Previous start-up experience desirable
  • Nephrology experience preferred
  • Experience with products in specialty pharmacy distribution
  • Demonstrated ability to plan, analyze and interpret sales data to identify and address business opportunities
  • Demonstrated proficiency with a Sales Force Automation application and basic business software
  • Well organized with the ability to multitask, prioritize, and manage shifting responsibilities in a dynamic, cross-functional teamwork environment
  • Excellent collaboration skills with strong attention to detail and the ability to multi-task and manage complexity
  • Strong interpersonal and organizational skills and excellent verbal and written communication skills are required
  • Must have a reliable and appropriate personal vehicle that meets minimum requirements to conduct business for the company
  • Background check including Motor Vehicle Record required
  • Ability to travel up to 30% domestically overnight required
  • The position is field based and the candidate must live in their territory or immediate adjacency
  • The ability to perform face to face work with colleagues and/or onsite in San Diego and the ability to satisfactorily meet credentialling requirements for access to healthcare facilities and customer sites within your territory on an ongoing basis, are essential job functions of this position

Travere Therapeutics focuses on creating and providing treatments for individuals with rare diseases, particularly those affecting the kidneys and metabolism. The company has developed several commercial therapies, including Thiola and Thiola EC for treating cystinuria, and Chenodal for managing gallstones. Additionally, it is working on new treatments, such as sparsentan, aimed at conditions like focal segmental glomerulosclerosis and IgA nephropathy. What sets Travere apart from other biopharmaceutical companies is its dedicated focus on rare diseases, which often receive less attention in the industry. The company's goal is to improve the lives of patients with these conditions by delivering effective therapies and offering support resources for patients and their families.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $144M funding supports clinical development and strategic initiatives.
  • EMA's expedited approval process could benefit Travere's European market pipeline.
  • Growing digital health platforms offer new patient engagement opportunities for Travere.

What critics are saying

  • Increased competition in IgA nephropathy market from Calliditas Therapeutics.
  • Challenging biotech market conditions may strain Travere's financial resources.
  • Loss of key personnel could impact clinical development projects.

What makes Travere Therapeutics unique

  • Focus on rare kidney and metabolic disorders sets Travere apart in biopharma.
  • Commercial products like Thiola and Chenodal provide a revenue stream for Travere.
  • Patient support programs enhance Travere's commitment to patient care and engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Travere Therapeutics
May 16th, 2025
Travere Therapeutics Announces Pricing of Public Offering of Common Stock

PDF Version Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million , before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024 , subject to customary closing conditions

Travere Therapeutics
Jan 23rd, 2025
Retrophin, LLC Completes Series A Financing | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

Travere Therapeutics
Jan 23rd, 2025
Retrophin Completes Reverse Merger With Desert Gateway, Inc. | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

CSIMarket
Nov 13th, 2024
Travere Therapeutics Raises $143.8M in Offering

Travere Therapeutics announced on November 12, 2024, that it raised approximately $144 million through a public offering, selling 8,984,375 shares at $16 each, including 1,171,875 shares from underwriters' overallotment options. The funds will support clinical development, operations, and strategic initiatives. This move comes amid challenging biotech market conditions and aims to address unmet medical needs in rare diseases. Travere also shared updates on its talent acquisition strategy.

Travere Therapeutics
Nov 11th, 2024
Travere Therapeutics Announces Pricing of Public Offering of Common Stock | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.